Hyperglycemia impairs acetylcholine-induced vasodilation of retinal arterioles through polyol pathway-independent mechanisms in rats

Journal of Pharmacological Sciences

Volumn 112, Issue 3, 2010, Pages 336-342

  Mori, Asami ^a   Saigo, Orie ^a   Sakamoto, Kenji ^a   Nakahara, Tsutomu ^a   Ishii, Kunio ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Aldose reductase; Diabetes; Endothelium; Polyol pathway; Retinal circulation

Indexed keywords

3 [(4,5,7 TRIFLUOROBENZOTHIAZOL 2 YL)METHYL] 5 METHYLPHENYLACETIC ACID; ACETYLCHOLINE; ALDOSE REDUCTASE INHIBITOR; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE; POLYOL; SORBITOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; BIOACCUMULATION; BLOOD VESSEL REACTIVITY; BODY WEIGHT; CATARACT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; HEART RATE; HYPERGLYCEMIA; IN VIVO STUDY; MALE; NONHUMAN; RAT; RETINA ARTERY; RETINA BLOOD FLOW; RETINA DISEASE; STREPTOZOCIN DIABETES; VASCULAR DISEASE; VASODILATATION;

EID: 77950672988     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09312FP     Document Type: Article

References (38)

1. Feke GT, Buzney SM, Ogasawara H, Fujio N, Goger DG, Spack NP, et al. Retinal circulatory abnormalities in type 1 diabetes. Invest Ophthalmol Vis Sci. 1994;35:2968-2975.
2. Ghirlanda G, Di Leo MA, Caputo S, Cercone S, Greco AV. From functional to microvascular abnormalities in early diabetic retinopathy. Diabetes Metab Rev. 1997;13:15-35.
3. Bursell SE, Clermont AC, Shiba T, King GL. Evaluating retinal circulation using video fluorescein angiography in control and diabetic rats. Curr Eye Res. 1992;11:287-295.
4. Horio N, Clermont AC, Abiko A, Abiko T, Shoelson BD, Bursell SE, et al. Angiotensin AT1 receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats. Diabetologia. 2004;47:113-123.
5. Clermont AC, Bursell SE. Retinal blood flow in diabetes. Microcirculation. 2007;14:49-61.
6. Nakazawa T, Kaneko Y, Mori A, Saito M, Sakamoto K, Nakahara T, et al. Attenuation of nitric oxide- and prostaglandin-independent vasodilation of retinal arterioles induced by acetylcholine in streptozotocin-treated rats. Vascular Pharmacol. 2007;46:153-159.
7. Nakazawa T, Mori A, Saito M, Sakamoto K, Nakaha-ra T, Ishii K. Vasodilator effects of adenosine on retinal arterioles in streptozotocin-induced diabetic rats. Naunyn Schmiedebergs Arch Pharmacol. 2008;376:423-430.
8. Mori A, Saigo O, Hanada M, Nakahara T, Ishii K. Hyperglycemia accelerates impairment of vasodilator responses to acetylcholine of retinal blood vessels in rats. J Pharmacol Sci. 2009;110: 160-168.
9. Chung SS, Chung SK. Aldose reductase in diabetic microvascular complications. Curr Drug Targets. 2005;6:475-486.
10. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res. 2007;55:498-510.
11. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.
12. Yamagishi S, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev. 2005;1:93-106.
13. Kato N, Yashima S, Suzuki T, Nakayama Y, Jomori T. Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complications. 2003;17:374-379.
14. Cheung AK, Fung MK, Lo AC, Lam TT, So KF, Chung SS, et al. Aldose reductase deficiency prevents diabetes-induced bloodretinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes. 2005;54:3119-3125.
15. Drel VR, Pacher P, Ali TK, Shin J, Julius U, El-Remessy AB, et al. Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. Int J Mol Med. 2008;21:667-676.
16. Ashizawa N, Yoshida M, Sugiyama Y, Akaike N, Ohbayashi S, Aotsuka T, et al. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats. Jpn J Pharmacol. 1997;73:133-144.
17. Yoshida M, Sugiyama Y, Akaike N, Ashizawa N, Aotsuka T, Ohbayashi S, et al. Amelioration of neurovascular deficits in diabetic rats by a novel aldose reductase inhibitor, GP-1447: minor contribution of nitric oxide. Diabetes Res Clin Pract. 1998;40: 101-112.
18. Kametaka S, Kasahara T, Ueo M, Takenaka M, Saito M, Sakamoto K, et al. A novel high resolution in vivo digital imaging system for the evaluation of experimental cataract in diabetic rats. J Pharmacol Sci. 2008;106:144-151.
19. Ludvigson MA, Sorenson RL.Immunohistochemical localization of aldose reductase. II. Rat eye and kidney. Diabetes. 1980;29: 450-459.
20. Akagi Y, Yajima Y, Kador PF, Kuwabara T, Kinoshita JH. Localization of aldose reductase in the human eye. Diabetes. 1984;33: 562-566.
21. Sato S, Secchi EF, Lizak MJ, Fukase S, Ohta N, Murata M, et al. Polyol formation and NADPH-dependent reductases in dog retinal capillary pericytes and endothelial cells. Invest Ophthalmol Vis Sci. 1999;40:697-704.
22. Takamura Y, Tomomatsu T, Kubo E, Tsuzuki S, Akagi Y. Role of the polyol pathway in high glucose-induced apoptosis of retinal pericytes and proliferation of endothelial cells. Invest Ophthalmol Vis Sci. 2008;49:3216-3223.
23. Chakrabarti S, Sima AA, Nakajima T, Yagihashi S, Greene DA. Aldose reductase in the BB rat: isolation, immunological identification and localization in the retina and peripheral nerve. Diabetologia. 1987;30:244-251.
24. Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes. 2004; 53:2404-2411.
25. Kador PF, Randazzo J, Blessing K, Makita J, Zhang P, Yu K, et al. Polyol formation in cell lines of rat retinal capillary pericytes and endothelial cells (TR-rPCT and TR-iBRB). J Ocul Pharmacol Ther. 2009;25:299-308.
26. Tesfamariam B, Brown ML, Cohen RA. Aldose reductase and myo-inositol in endothelial cell dysfunction caused by elevated glucose. J Pharmacol Exp Ther. 1992;263:153-157.
27. Tesfamariam B, Palacino JJ, Weisbrod RM, Cohen RA. Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol. 1993;21:205-211.
28. Toth E, Racz A, Toth J, Kaminski PM, Wolin MS, Bagi Z, et al. Contribution of polyol pathway to arteriolar dysfunction in hyperglycemia. Role of oxidative stress, reduced NO, and enhanced PGH2/TXA2 mediation. Am J Physiol Heart Circ Physiol. 2007;293:H3096-H3104.
29. Campbell WB, Gebremedhin D, Pratt, PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996;78:415-423.
30. Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998;396:269-272.
31. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000;106:1521-1530.
32. Sandow SL, Tare M, Coleman HA, Hill CE, Parkington HC. Involvement of myoendothelial gap junctions in the actions of endothelium-derived hyperpolarizing factor. Circ Res. 2002;90: 1108-1113.
33. Chauhan SD, Nilsson H, Ahluwalia A, Hobbs AJ. Release of Ctype natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci U S A. 2003;100:1426-1431.
34. Zhang SX, Ma JX, Sima J, Chen Y, Hu MS, Ottlecz A, et al. Genetic difference in susceptibility to the blood-retina barrier breakdown in diabetes and oxygen-induced retinopathy. Am J Pathol. 2005;166:313-321.
35. Mandecka A, Dawczynski J, Blum M, Müller N, Kloos C, Wolf G, et al. Influence of flickering light on the retinal vessels in diabetic patients. Diabetes Care. 2007;30:3048-3052.
36. Yoshida A, Kojima M, Ogasawara H, Ishiko S. Oscillatory potentials and permeability of the blood-retinal barrier in noninsulin-dependent diabetic patients without retinopathy. Ophthalmology. 1991;98:1266-1271.
37. Sakai H, Tani Y, Shirasawa E, Shirao Y, Kawasaki K. Development of electroretinographic alterations in streptozotocin-induced diabetes in rats. Ophthalmic Res. 1995;27:57-63.
38. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998;102:783-791.